ALL NEWS

Merck says experimental pill cuts worst effects of COVID-19

Oct 1, 2021, 7:18 AM
This undated image provided by Merck & Co. shows their new antiviral medication. Pharmaceutical...
This undated image provided by Merck & Co. shows their new antiviral medication. Pharmaceutical company Merck & Co. said Friday, Oct. 1, 2021, that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the U.S. and around the world to authorize its use. (Merck & Co. via AP)
(Merck & Co. via AP)

WASHINGTON (AP) — Drugmaker Merck said Friday that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the U.S. and around the world to authorize its use.

If cleared, the drug would be the first pill shown to treat COVID-19, a potentially major advance in efforts to fight the pandemic. All COVID-19 therapies now authorized in the U.S. require an IV or injection.

Merck and its partner Ridgeback Biotherapeutics said early results showed patients who received the drug, called molnupiravir, within five days of COVID-19 symptoms had about half the rate of hospitalization and death as patients who received a dummy pill. The study tracked 775 adults with mild-to-moderate COVID-19 who were considered higher risk for severe disease due to health problems such as obesity, diabetes or heart disease.

Among patients taking molnupiravir, 7.3% were either hospitalized or died at the end of 30 days, compared with 14.1% of those getting the dummy pill. There were no deaths in the drug group after that time period compared with eight deaths in the placebo group, according to Merck. The results were released by the company and have not been peer reviewed by outside experts, the usual procedure for vetting new medical research. Merck said it plans to present them at a future medical meeting.

An independent group of medical experts monitoring the trial recommended stopping it early because the interim results were so strong. That is typical when early results so clearly show a treatment works that there is no need for further testing before applying for authorization. Company executives said they plan submit the data for review by the Food and Drug Administration in coming days. Once the submission is complete, the FDA could make a decision within weeks — and, if approved, the drug could be on the market soon after.

“It exceeded what I thought the drug might be able to do in this clinical trial,” said Dr. Dean Li, vice president of Merck Research Laboratories. “When you see a 50% reduction in hospitalization or death that’s a substantial clinical impact.”

Side effects were reported by both groups in the Merck trial, but they were slightly more common among the group that received a dummy pill. The company did not specify the problems.

Patients take the pill twice a day for five days to complete a course of treatment.

Earlier study results showed the drug did not benefit patients who were already hospitalized with severe disease.

The U.S. has approved one antiviral drug, remdesivir, specifically for COVID-19, and allowed emergency use of three antibody therapies that help the immune system fight the virus. But all the drugs have to given by IV or injection at hospitals or medical clinics, and supplies have been stretched by the latest surge of the delta variant.

Health experts including the top U.S. infectious disease expert Dr. Anthony Fauci have long called for a convenient pill that patients could take when COVID-19 symptoms first appear, much the way the standard flu medication Tamiflu helps fight influenza. Such medications are seen as key to controlling future waves of infection and reducing the impact of the pandemic.

Merck’s pill works by interfering with the coronavirus’s ability to copy its genetic code and reproduce itself. It has shown similar activity against other viruses.

The U.S. government has committed to purchase 1.7 million doses of the drug if it is authorized by the FDA. Merck has said it can produce 10 million doses by the end of the year and has contracts with governments worldwide. The company has not announced prices.

Several other companies, including Pfizer and Roche, are studying similar drugs that could report results in the coming weeks and months.

Merck had planned to enroll more than 1,500 patients in its late-stage trial before the independent board stopped it early. The results reported Friday included patients enrolled across Latin America, Europe and Africa. Executives estimated about 10% of patients studied were from the U.S.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Today’s Top Stories

All News

The Utah Department of Agriculture and Food announced Wednesday two new cases of avian influenza....
Mark Jones

Two new cases of avian influenza announced Wednesday

Two new cases of avian influenza have been confirmed by the Utah Department of Agriculture and Food. The new cases are in Iron and Utah counties.
22 hours ago
A suspect is in custody Wednesday evening after University of Utah Police say two hidden cameras we...
Mark Jones

Hidden cameras found in restrooms in U of U Student Life Center, suspect in custody

University of Utah Police say a suspect has been arrested after two hidden cameras were found inside two different restrooms inside the Student Life Center.
22 hours ago
Salt Lake City Police took a 44-year-old man into custody on Wednesday in connection to the burglar...
Mark Jones

SLC Police arrest man for burglarizing two law offices

Salt Lake City Police say a 44-year-old man was arrested Wednesday in connection to burglarizing two downtown law offices last week.
22 hours ago
Former Salt Lake City Mayor Rocky Anderson wants his old job back. ...
Mark Jones

Rocky Anderson announces bid to run for SLC mayor in 2023

Former Salt Lake City Mayor Rocky Anderson announced Wednesday that he is seeking reelection to get his old job back.
22 hours ago
Orem auto-pedestrian collision...
Mark Jones

Two people hurt in auto-pedestrian collision in Orem

Orem police are investigating an auto-pedestrian collision that sent two people to the hospital Wednesday afternoon.
22 hours ago
Fatal car crash...
Waverly Golden

Salt Lake City Police investigate deadly auto-pedestrian collision

SLC 9-1-1 received information about a deadly auto-pedestrian collision involving a Nissan pick-up Wednesday afternoon, according to Salt Lake City Police Department.
22 hours ago

Sponsored Articles

Happy joyful smiling casual satisfied woman learning and communicates in sign language online using...
Sorenson

The best tools for Deaf and hard-of-hearing workplace success

Here are some of the best resources to make your workplace work better for Deaf and hard-of-hearing employees.
Team supporters celebrating at a tailgate party...
Macey's

8 Delicious Tailgate Foods That Require Zero Prep Work

In a hurry? These 8 tailgate foods take zero prep work, so you can fuel up and get back to what matters most: getting hyped for your favorite
christmas decorations candles in glass jars with fir on a old wooden table...
Western Nut Company

12 Mason Jar Gift Ideas for the 12 Days of Christmas [with recipes!]

There are so many clever mason jar gift ideas to give something thoughtful to your neighbors or friends. Read our 12 ideas to make your own!
wide shot of Bear Lake with a person on a stand up paddle board...

Pack your bags! Extended stays at Bear Lake await you

Work from here! Read our tips to prepare for your extended stay, whether at Bear Lake or somewhere else nearby.
young boy with hearing aid...
Sorenson

Accommodations for students who are deaf and hard of hearing

These different types of accommodations for students who are deaf and hard of hearing can help them succeed in school.
Young woman receiving laser treatment...
Form Derm Spa

How facial plastic surgery and skincare are joining forces

Facial plastic surgery is not only about looking good but about feeling good too. The medical team at Form Spa are trained to help you reach your aesthetic outcomes through surgery and through skincare and dermatology, too.
Merck says experimental pill cuts worst effects of COVID-19